ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,303.27
0.12%
Dow Jones
40,003.59
0.34%
US Dollar vs MXN
16.6086
0.00%
Brent Oil
83.76
0.00%
Bitcoin
67,284.63
0.30%
Registration Strip Icon for default Regístrate gratis para obtener cotizaciones en tiempo real, gráficos interactivos, flujo de opciones en vivo y más.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Lixte Biotechnology Holdings Inc (LIXT)

  7. Lixte Biotechnology Holdings Inc (LIXT) Noticias

LIXT

Lixte Biotechnology (LIXT)

Lixte Biotechnology Holdings Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:LIXT
FechaHoraFuenteTítuloSímboloCompañía
08/05/202408:25GlobeNewswire Inc.LIXTE Biotechnology Co-Sponsoring International Scientific Conference on “Therapeutic Over-Activation in Cancer”NASDAQ:LIXTLixte Biotechnology Holdings Inc
24/04/202414:25AllPennyStocks.comMixed Shelf Filing Gives Micro Cap Delayed BoostNASDAQ:LIXTLixte Biotechnology Holdings Inc
27/03/202414:35AllPennyStocks.comBiotech Steals The Show Following Pre-Clinical Data AnnouncementNASDAQ:LIXTLixte Biotechnology Holdings Inc
27/03/202407:30GlobeNewswire Inc.NEW SCIENTIFIC PUBLICATION SHOWS LB-100, LIXTE’S LEAD CLINICAL COMPOUND, CAN FORCE CANCER CELLS TO GIVE UP THEIR CANCER-CAUSING PROPERTIESNASDAQ:LIXTLixte Biotechnology Holdings Inc
21/03/202407:30GlobeNewswire Inc.LIXTE Provides Update on Progress with LB-100 as a PP2A Inhibitor to Enhance Chemotherapy and Immunotherapy Cancer TreatmentsNASDAQ:LIXTLixte Biotechnology Holdings Inc
27/02/202415:59Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LIXTLixte Biotechnology Holdings Inc
27/02/202407:30GlobeNewswire Inc.Professor René Bernards to Present New Pre-Clinical Data on LIXTE’s LB-100 at Joint Conference of European and American Associations for Cancer ResearchNASDAQ:LIXTLixte Biotechnology Holdings Inc
26/02/202407:30GlobeNewswire Inc.LIXTE Biotechnology Enters into Exclusive Immune Oncology Patent License Agreement with NINDS and NCINASDAQ:LIXTLixte Biotechnology Holdings Inc
29/01/202407:30GlobeNewswire Inc.First Patient Dosed with LIXTE’s LB-100 and GSK’s Immunotherapy Dostarlimab-gxly in Ovarian Clear Cell Carcinoma TrialNASDAQ:LIXTLixte Biotechnology Holdings Inc
13/11/202307:30GlobeNewswire Inc.LIXTE Biotechnology Provides Update on Clinical Progress and Expanding CollaborationsNASDAQ:LIXTLixte Biotechnology Holdings Inc
09/11/202316:16Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:LIXTLixte Biotechnology Holdings Inc
16/10/202313:51Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LIXTLixte Biotechnology Holdings Inc
16/10/202307:30GlobeNewswire Inc.LIXTE, Netherlands Cancer Institute, and Oncode Institute to Expand CollaborationNASDAQ:LIXTLixte Biotechnology Holdings Inc
10/10/202314:55Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:LIXTLixte Biotechnology Holdings Inc
10/10/202314:47Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:LIXTLixte Biotechnology Holdings Inc
09/10/202307:30GlobeNewswire Inc.LIXTE Biotechnology Holdings Announces the Passing of its Founder, John S. KovachNASDAQ:LIXTLixte Biotechnology Holdings Inc
05/10/202319:39Edgar (US Regulatory)Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]NASDAQ:LIXTLixte Biotechnology Holdings Inc
29/09/202315:05Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:LIXTLixte Biotechnology Holdings Inc
26/09/202307:30GlobeNewswire Inc.LIXTE Appoints Bas van der Baan as President and Chief Executive OfficerNASDAQ:LIXTLixte Biotechnology Holdings Inc
20/09/202307:30GlobeNewswire Inc.LIXTE Biotechnology Announces a Supported Collaborative Trial to Study LIXTE’s First-in-Class PP2A Inhibitor, LB-100, Plus GSK’s Immunotherapy, Dostarlimab, in Clear-Cell Ovarian CancerNASDAQ:LIXTLixte Biotechnology Holdings Inc
21/08/202323:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:LIXTLixte Biotechnology Holdings Inc
11/08/202315:20Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:LIXTLixte Biotechnology Holdings Inc
01/08/202314:37Edgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:LIXTLixte Biotechnology Holdings Inc
20/07/202315:25Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:LIXTLixte Biotechnology Holdings Inc
20/07/202315:05GlobeNewswire Inc.LIXTE Biotechnology Announces Closing of $3.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market under Nasdaq RulesNASDAQ:LIXTLixte Biotechnology Holdings Inc
18/07/202307:00GlobeNewswire Inc.LIXTE Biotechnology Announces Pricing of $3.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market under Nasdaq RulesNASDAQ:LIXTLixte Biotechnology Holdings Inc
17/07/202307:30GlobeNewswire Inc.Preclinical Results of LIXTE Biotechnology’s Collaboration with Netherlands Cancer Institute Reveal Novel Mechanism by which LIXTE’s Lead Clinical Compound LB-100 Enhances Effectiveness of Immunotherapy and ChemotherapyNASDAQ:LIXTLixte Biotechnology Holdings Inc
26/06/202305:16Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:LIXTLixte Biotechnology Holdings Inc
23/06/202307:30GlobeNewswire Inc.LIXTE Biotechnology Holdings, Inc. Regains Compliance with Nasdaq Continued Listing RequirementsNASDAQ:LIXTLixte Biotechnology Holdings Inc
07/06/202307:30GlobeNewswire Inc.LIXTE Biotechnology and the Spanish Sarcoma Group Enroll First Patient in a Phase 1b/2 Randomized Trial of Doxorubicin +/- LIXTE’s Lead Anti-Cancer Compound, LB-100, in Advanced Soft Tissue SarcomasNASDAQ:LIXTLixte Biotechnology Holdings Inc
 Showing the most relevant articles for your search:NASDAQ:LIXT

Su Consulta Reciente

EU
W967S
W967S
COIN
KPCCUSD
KOLOOP BASIC
USOTC
NXFTY
Next 15 (PK)
USOTC
PFPLF
Propel Funeral Partners (PK)
LSE
ESR
Ensor
ASX
TUA
Tuas
TG
8TI
Stellantis NV
LSE
72KX
Esic Sukuk 24
NASDAQ
NCBC
COIN
ETHBRL
Ethereum
EU
ITXT
Intexa
BMF
WDOQ24
WDOQ24 - Agosto 2024
USOTC
PDGRD
PDG Realty (CE)
LSE
AU69
Lloyds Bkg.31
NASDAQ
RUSPX
U.S. Strategic Equity Fu...
COIN
BZTBTC
Bloomzed Token
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados